Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738764 · ClinicalTrials.gov registry record · Phase 1
A Trial of PDL192 in Subjects With Advanced Solid Tumors
A Phase 1 study of Cancer, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00738764 is a Phase 1 study of Cancer that has completed, run by Abbott. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00738764, a Phase 1 study of Cancer, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL PDL192
Study Locations (2)
Arizona
- Site Reference ID/Investigator# 53365 - Scottsdale
Colorado
- Site Reference ID/Investigator# 53364 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738764
The ClinicalTrials.gov registry entry for NCT00738764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which PDL192 is the first listed.
NCT00738764 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00738764 about?
NCT00738764 is a clinical study titled "A Trial of PDL192 in Subjects With Advanced Solid Tumors". This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
What is the current status of trial NCT00738764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-07. Estimated completion is 2011-10.
What conditions does trial NCT00738764 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00738764?
The interventions under investigation include: PDL192 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00738764?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00738764 being conducted?
This trial has 2 study locations across Arizona, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.